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ABSTRACT - Introduction: With an increased understanding of myocardial infarction, 
human mesenchymal stem cell (hMSC) transplantation therapies have shown promising 
results as a possible treatment for heart failure. However, little is known about mitochondrial 
biogenesis for hMSCs transplanted to a cardiac microenvironment, though mitochondria are 
vital to cell energy production, cellular differentiation, and cell death. The purpose of this 
study was to investigate the role of mitochondrial biogenesis in adult hMSC differentiation 
and acquisition of a cardiac phenotype.  Based on recent experimental evidence, we 
hypothesized that mitochondrial activity would be enhanced when hMSC differentiation was 
directed towards a cardiac-like fate.   
Methods: Two models to direct hMSC differentiation to a cardiac-like phenotype were 
evaluated. In Model # 1, hMSCs were co-cultured with neonatal rat cardiomyocytes for 48 
hours.  In Model # 2, hMSCs were treated with a combination of 3 growth factors (GF): 
insulin-like growth factor-1 (IGF-1), fibroblast growth factor-2 (FGF-2), and bone 
morphogenetic protein-2 (BMP-2) for 48 hours and 2.5 weeks. For both models qRT-PCR 
was performed on Mitochondrial Transcription Factor B1(TFB1M), Ubiquinol-Cytochrome 
C Reductase Core Protein 1(UQCRC1), Nuclear Respiratory Factor 1 (NRF-1), and 
Myocyte-specific Enhancer Factor 2C (MEF2C). In GF treated hMSCs, protein expression of 
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N-cadherin and mitochondrial Electron Transport Chain (ETC) complexes II, III, IV and V 
were evaluated, and mitochondrial O2 consumption was assessed.   
Results: Co-cultured hMSCs showed increased mitochondrial and cardiac specific gene 
expression when compared to control for TFB1M, UQCRC1, and MEF2C (p≤0.05). GF 
treated hMSCs showed increased mitochondrial gene expression of TFB1M (p<0.05), 
increased O2 consumption, and increased protein expression of mitochondrial ETC complex 
II and N-cadherin. No significant differences in cardiac specific gene expression were 
observed in GF treated hMSCs.  
Conclusions: Both Models # 1 and # 2 exhibited various levels of increased mitochondrial 
biogenesis. Results from Model # 1 hMSCs suggest increased mitochondrial gene expression 
in early co-cultures, specifically Complex III, may play a role in early hMSC differentiation 
into a cardiac-like phenotype. Results of Model # 2 hMSCs suggest enhanced mitochondrial 
biogenesis with GF treatment and increased culture time may lead to improved hMSC 
survival and proliferation to enhance cell transplantation therapies.   
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I. INTRODUCTION 
 Due to an increased understanding of myocardial infarction (MI) and development of 
congestive heart failure, stem cell transplantation therapies are being pursued as a therapeutic 
alternative to organ transplantation. Specifically, human mesenchymal stem cells (hMSCs) 
are a component of new cardiovascular cell based therapies. HMSCs are bone marrow 
derived pluripotent stem cells that proliferate and differentiate into a variety of specialized 
tissues including liver, neurons, fat, tendons, and muscle; possess immunomodulatory 
properties; and involve no ethical or immunological issues (Fukuhara et al. 1470-1480; Xu et 
al. 2658-2665; Labovsky et al. 93-101). HMSCs have also been demonstrated to differentiate 
into “cardiac-like cells” when placed in vivo and in vitro cardiac microenvironments (Kubo 
et al. 26-32; Labovsky et al. 93-101; Xu et al. 2658-2665; Fukuhara et al. 1470-1480; Muller-
Borer et al. e38454). Yet, when transplanted, the precise mechanisms of stem cell survival, 
engraftment, and differentiation are not well understood (Pittenger and Martin 9-20). Due to 
this lack of understanding and hMSC’s differentiation potential into many cell types, 
complications may occur during cell transplantation for cardiac therapy (Breitbach et al. 
1362-1369; Li et al. 295-303; Labovsky et al. 93-101). Thus, elucidation of the factors that 
direct hMSC differentiation to a cardiac-like phenotype may improve therapeutic efficiency.  
 Differentiating hMSCs in co-culture models with neonatal rat cardiomyocytes is an 
accepted method to study hMSC cardiac-like differentiation (Labovsky et al. 93-101; 
Fukuhara et al. 1470-1480; Xu et al. 2658-2665; Li et al. 295-303). In co-culture, hMSCs 
exhibit cardiomyocyte like properties through cell-cell communication including the 
expression of cardiac specific genes and proteins along with Ca
2+
 excitation-contraction 
coupling (Muller-Borer et al. e38454). In this model, several signaling pathways including 
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Ca
2+
 dependent pathways have been studied and proposed as a signal to drive cardiac-like 
cell differentiation (Muller-Borer et al. e38454). Further studies are needed to elucidate other 
signaling pathways directing hMSC differentiation into cardiac like cells.  
 Another method for directing hMSC differentiation is through GF treatment of 
hMSCs in monoculture. This model has been shown to increase cardiac transcription factors 
and proteins similar to the co-culture model suggesting the GF treated hMSC model’s 
intrinsic ability to differentiate into cardiac-like cells (Hahn et al. 933-943). When treated 
with a combination of GFs, hMSCs show increased survival in cardiac transplantation and 
improved therapeutic efficiency at sites with myocardial infarctions (Hahn et al. 933-943). 
Gap junction mediated cell-cell signaling and other signaling pathways that may direct GF 
treated hMSCs are under investigation. An understanding of the hMSC differentiation 
signaling pathway is critical for improved stem cell differentiation and therapy.   
 A possible signaling pathway involved in hMSC differentiation towards a cardiac-like 
phenotype is the mitochondrial biogenesis pathway. The role of mitochondrial biogenesis and 
bioenergetic function in adult stem cells currently remains largely unexplored, even though 
mitochondria are important in cell energy production, cell signaling, cellular differentiation, 
cell growth, and cell death (Duchen 365-451; Cho et al. 1472-1478; Facucho-Oliveira et al. 
4025-4034; Piccoli et al. 26467-26476; Chung et al. S60-7). Improper functioning of this 
unique organelle has led to many mitochondrial maladies that have been linked to a wide 
range of disorders, including diabetes, cardiovascular disease, and cancer (Lonergan, 
Bavister, and Brenner 289-296; Duchen 365-451; Nesti et al. 165-171). Recently, the concept 
of mitochondrial biogenesis has been emerging as a concept critical to hMSC differentiation 
into various cell types and other advanced lineages (Pietila et al. 435-445; Nesti et al. 165-
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171; Pietila et al. 575-588; Chen et al. 960-968). Thus, the goal of this study is to improve 
our basic understanding of stem cell differentiation in cardiac tissue regeneration and repair 
by investigating the role of mitochondrial biogenesis in adult hMSC differentiation and 
acquisition of a cardiac phenotype in a simulated cardiac co-culture microenvironment and in 
a growth factor treated monoculture model. Based on recent experimental evidence and new 
genomic data, it was hypothesized that mitochondrial activity and biogenesis would be 
enhanced in hMSCs when placed in a microenvironment to direct cardiomyocyte 
differentiation. 
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II. MATERIALS AND METHODS  
Two cell culture models reported to direct hMSCs towards a cardiac like phenotype 
were used in this investigation. In Model # 1, hMSCs were co-cultured with neonatal rat 
cardiac myocytes or grown in monoculture as a control for 48 hours. After 48 hours, the 
following experiments were performed in control and co-cultured hMSCs:  
 CD 90 magnetic bead separation to isolate hMSCs  
 qRT-PCR to evaluate cardiac and mitochondrial gene expression  
Study limitations prevented further analysis in Model # 1; therefore, Model # 2 (GF treated 
hMSCs) was studied. 
In Model # 2, hMSCs were treated with a combination of GFs and evaluated at 48 
hours and 2.5 weeks. For hMSCs treated with GFs for 48 hours, qRT-PCR was performed to 
evaluate differences in mitochondrial gene expression between control and GF treated 
hMSCs. For hMSCs treated with GFs for 2.5 weeks, the following experiments were 
completed: 
 qRT-PCR to evaluate cardiac and mitochondrial gene expression  
 Western blot analysis to evaluate cardiac and mitochondrial protein expression 
 O2 consumption to evaluate mitochondrial content and oxidative capacity 
 2D/3D Imaging with 3D reconstruction analysis to evaluate mitochondrial 
localization and morphology 
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A. Cell Culture and Separation 
Frozen vials of dsRed hMSCs (from healthy donors transduced with dsRed 
fluorescent protein) were purchased from the Tulane Center for the Preparation and 
Distribution of Adult Stem Cells and Tulane Center of Gene Therapy. Prior to shipping, 
the hMSCs were transduced with the lentiviral vector WPT-EF1 short-DsRed2-mito 
pseudotyped with a Vesicular stomatitis virus G protein envelope in the presence of 
polybrene. Fluorescence Activated Cell Sorting (FACS) isolation was used to positively 
select for hMSCs with dsRed fluorescent protein. The vector encodes a dsRed 
fluorophore that stably targets subunit VIII of cytochrome c oxidase (mitochondrial ETC 
complex IV) under the control of the EF1-short promoter.     
1. Model # 1 – hMSC co-culture with cardiomyocytes and separation 
a. Cardiomyocyte Isolation and Culture 
Cardiomyocyte primary cultures were established in order to make a 
myocardial microenvironment for the hMSCs. Neonatal rat cardiomyocytes were 
isolated from the hearts of 1 day old Sprague Dawley rats using a Worthington 
Neonatal Cardiomyocyte Isolation System (Worthington Biochemical Corp., 
Lakewood, NJ) in accordance with accepted guidelines for the care and treatment 
of experimental animals at East Carolina University’s Brody School of Medicine 
and the National Institutes of Health. The cardiomyocytes were grown for 5 days 
in Richter (Irvine Scientific, Santa Ana, CA) medium supplemented with 10% 
Fetal Bovine Serum (FBS) before co-culturing with hMSCs. 
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b. Model # 1 - Co-cultured hMSCs 
HMSCs were co-cultured with neonatal rat cardiomyocytes in a 1:10 ratio 
(hMSCs to cardiomyocytes) in flasks and grown in a cell culture incubator (5% 
CO2 and 37°C) with full media (16.5% FBS in Dulbecco’s Modified Eagle 
Medium [DMEM]). The control hMSCs were grown in monocultures under 
identical conditions, i.e. incubator environment, full media, and length of time in 
culture.  
c. CD 90 Magnetic bead separation 
After 48 hours of co-culture, the hMSCs were separated from the cardiac 
myocytes using a CD 90 magnetic bead separation procedure following the 
vendor’s protocol (DYNAL - Dynabeads® Pan Mouse IgG from Invitrogen). CD 
90, a stem cell marker located on the cell membrane surface, is expressed on 
hMSCs. Magnetically labeled CD 90 Microbeads were added to a cell suspension 
containing the co-cultured hMSCs and cardiomyocytes and a cell suspension 
containing the control hMSCs (indirect technique). In both cell suspensions, the 
CD 90 antibody on the magnetic microbeads binded to the respective CD 90 stem 
cell marker on the hMSC membrane surface. The suspensions were passed 
through a magnetic separation column, where a magnet isolated the labeled 
hMSCs leaving any unlabeled cells including co-cultured cardiomyocytes and 
unlabeled hMSCs to elute through the column and be collected as eluate. The 
isolated hMSCs were collected and harvested to evaluate cardiac and 
mitochondrial gene expression with qRT-PCR. The control hMSCs were treated 
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to the same separation protocol. RLT buffer was added to harvested hMSCs to 
isolate and preserve the RNA for qRT-PCR.  
2. Model # 2 – GF Treated hMSCs 
 In Model # 2, hMSCs were plated in flasks and grown in a cell culture 
incubator (5% CO2 and 37°C) with full media and antibiotics (16.5% FBS and 1% 
Penicillin/Streptomycin in DMEM) along with a combination of 3 GFs. The 3 GFs 
used in the experiment were IGF-1 (2 ng/mL), FGF-2 (50 ng/mL), and BMP-2 (10 
ng/mL). GFs were added to hMSCs during each media change every 3-4 days (for 
hMSCs treated with GFs for 2.5 weeks). The control hMSCs were grown under 
identical conditions as the GF treated hMSCs but without GFs. After 48 hours or 2.5 
weeks in culture, the hMSCs were harvested. TrypLE express recombinant trypsin 
(Gibco 12605) was added to flasks containing hMSCs and incubated for 5 minutes at 
37°C in order to lift cells off the flask. Full media with FBS was added after 5 
minutes to stop the trypsin enzyme activity. Cells suspended in full media were 
collected in 50 mL conical tubes and spun in a centrifuge at 1500 RPM for 5 minutes 
in order to precipitate cell pellets. The pellets were washed with sterile Phosphate 
Buffered Solution (PBS) and re-suspended in fresh media for hMSCs to be counted 
on a hemacytometer. RLT buffer was added to isolated hMSCs to preserve the RNA 
for qRT-PCR. For western blot analysis, cell pellets were resuspended in Tris-
buffered saline (TBS) for washing. Afterwards, lysis buffer was added for western 
blot analysis. 
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B. Cardiac and Mitochondrial Gene Expression with qRT-PCR 
1.  Extraction and Quantification of RNA 
 All hMSCs harvested in Model # 1 (the control hMSCs, the isolated hMSCs, 
and the cardiomyocytes), all hMSCs harvested in Model # 2 after 48 hours of GF 
treatment (control and GF treated), and 5.0 x 10
6
 hMSCs harvested from each group 
in Model # 2 after 2.5 weeks of GF treatment (control and GF treated) were lysed by 
adding RLT buffer from a RNeasy mini kit (Qiagen Cat. # 74104) for RNA isolation 
and preservation in order to evaluate gene expression via qRT-PCR. After preserving 
the RNA with RLT buffer, ethanol along with RW1 and RPE buffer from the RNeasy 
mini kit was used to extract RNA from the lysed cell contents. Afterwards, the 
extracted RNA was taken to the NanoDrop 1000 Spectrophotometer to measure RNA 
yield.   
2.  Synthesis of cDNA and qRT-PCR 
RT master mix (High Capacity cDNA Reverse Transcription Kit – Invitrogen 
part # 4368814) was added to quantified RNA and placed in a ABI 7300 
thermocycler to synthesize cDNA. The ABI temperature and time conditions for 
synthesizing cDNA are identified in Table 1A as a total of 4 steps. In Step 1, the 
primers used in cDNA synthesis were extended at 25°C for 10 minutes. In Steps 2 
and 3, cDNA was synthesized at 37°C. Afterwards, cDNA synthesis was completed 
by terminating the reaction at 85°C in Step 4.  
The synthesized cDNA was added to 96 well plates with TaqMan Master Mix 
and TaqMan gene probes to conduct qRT-PCR. The 96 well plates were placed in the 
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thermocycler again to synthesize copies of RNA selected by the gene probes. The 
ABI temperature and time conditions for qRT-PCR are identified in Table 1B. The 
first two steps were used to initiate reverse transcription. Afterwards, Steps 3 and 4 
were repeated 40 times sequentially. Step 3 was used for denaturing cDNA, and Step 
4 was used for annealing and extending the cDNA strands.  The ct values were 
recorded and used to evaluate gene expression as fold difference in the monoculture 
control vs. the co-cultured hMSCs in Model # 1 and in the control vs. the GF treated 
hMSCs in Model # 2.  
In Models # 1 and # 2, qRT-PCR was conducted to evaluate cardiac and 
mitochondrial gene expression. The cardiac genes tested for gene expression have 
been shown to be expressed during cardiac differentiation and in cardiomyocytes. To 
evaluate mitochondrial gene expression, potentially significant mitochondrial 
biogenesis genes were identified from querying the GEO Microarray Database 
(NCBI-GEO data base accession number GSE32171) obtained by the Muller-Borer 
laboratory for the co-culture model (Muller-Borer et al. e38454). Shown below in 
Table 2 is a description of the cardiac and mitochondrial genes used as TaqMan gene 
probes for qRT-PCR in Models # 1 and # 2.  
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Table 1: Temperature and Time Conditions in ABI 7300 thermocycler  
Table 1A: ABI Thermocycler Conditions for Synthesizing cDNA 
 Step 1  Step 2  Step 3  Step 4 
Temperature (°C) 25 37 37 85 
Time (min.)  10  60 60 5 
 
Table 1B: ABI Thermocycler Conditions for qRT-PCR 
 
Step 1 Step 2 Step 3 Step 4 
Cycles   40 Cycles – Step 3 ->Step 4 (Repeat) 
Temperature (°C) 
50 95 95 60 
Time (min.) 
2 10 0.25 1 
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Table 2: Summary of Cardiac and Mitochondrial Genes  
Gene Type Abbreviation Full name Description 
Cardiac Genes 
BNP Brain Natriuretic Peptide 
Natriuretic peptide synthesized within the 
ventricles and encodes a secreted protein 
that functions as a cardiac hormone 
CAMTA1 
Calmodulin-binding 
transcription activator 1 
 
Expressed in brain tissue, heart, and 
kidney; interacts with and possibly 
regulates calmodulin, a universal calcium 
sensor; and functions as a transcriptional 
activator 
Cx43 Connexin 43 
Gap junction found in ventricular 
myocardium and is also known as the main 
cardiac connexin 
MEF2C 
Myocyte-specific enhancer 
factor 2C 
Transcription factor found at all stages of 
cardiac development and is up regulated 
with cell hypertrophy  
MYOCD Myocardin 
Regulates cardiac and smooth muscle gene 
expression 
Mitochondrial 
Genes* 
MFN2 Mitofusin-2 
Involved in mitochondrial fusion and 
contributes to maintenance of 
mitochondrial viability in cells 
MT-CO1 
Mitochondrially encoded 
Cytochrome c oxidase I 
Encodes protein from mitochondrial DNA 
to form an ETC complex IV subunit 
NRF-1 
Nuclear Respiratory Factor 
1 
Functions as a transcription factor for 
activating metabolic genes, and is involved 
in early stages of mitochondrial biogenesis 
in muscle development 
TFB1M 
Mitochondrial Transcription 
Factor B1 
Encodes a mitochondrial transcription 
factor that is suggested to activate key 
genes in mitochondrial biogenesis 
UCP3 
Mitochondrial Uncoupling 
Protein 3 
Reduces the mitochondrial membrane 
potential as a proton leak, and is involved 
in negating oxidative stress 
UQCRC1 
Ubiquinol-cytochrome c 
reductase core protein 1 
Encodes protein from nuclear DNA to 
form an ETC complex III subunit 
 
*: Mitochondrial genes in Table 2 considered significant in the queried GEO Microarray Database  
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C. Western Blot Analysis in Model # 2 
The lysis buffer added to cell pellets for western blot analysis was 0.5% of Triton 
X-100 and 0.1% of Protease Inhibitor Cocktail (Sigma P8340) in TBS (pH = 7.2). After 
vortexing and centrifuging, the cell lysate in the supernatant was obtained and the 
insoluble debris was discarded. Protein concentration from cell lysate was quantified via 
a standard curve analysis. Afterwards, protein samples were prepared in 1X NuPage 
lithium dodecyl sulfate (LDS) sample buffer and in the reducing agent 1X dithothreitol 
(DDT). Western blot analysis was performed by loading 60 ug of protein sample per well 
in a BioRad 4-12% Bis Tris gel. After running the gel with NuPage MOPS running buffer 
via electrophoresis (175 V for 55 minutes), the gel was transferred to a Nitrocellulose 
membrane (60 V for 1 hour and 15 minutes) with Towbins transfer buffer. Once transfer 
was complete, the membrane was blocked with 5% milk in TBS. Washes were completed 
between the additions of the primary and secondary antibody using 0.1 % Tween 20 in 
TBS. The following primary antibodies (diluted with 5 % milk in TBS) shown in Table 3 
were added to the membrane after washing 3 times. After adding the primary antibodies 
to the membrane and washing again for 3 times, a secondary antibody tagged with 
horseradish peroxidase (HRP) from Invitrogen
TM
 was added. A chemiluminescent 
substrate was added to the membrane to detect HRP. The membrane was exposed to 
photographic film. The exposed film was developed by a film developer. The bands on 
the developed film underwent densitometric analysis to evaluate the relative amount of 
protein as a percent of the control.    
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Table 3: Summary of Primary and Secondary Antibodies for Western Blot Analysis 
Primary Antibody Secondary Antibody Description 
Mouse Anti-Human Connexin-
43 Monoclonal Antibody 
Goat Anti-Mouse 
 
Used to determine protein 
expression of gap junction 
protein (the main cardiac 
connexin) 
Mouse Anti-Human N-Cadherin  Goat Anti-Mouse 
 
Used to determine protein 
expression of a cell adhesion 
transmembrane protein 
Mouse Anti-Human Total 
OXPHOS Antibody 
Goat Anti-Mouse 
 
Used to determine protein 
expression of mitochondrial 
ETC Complexes I-V 
Rabbit Anti-Human β-actin  Goat Anti-Rabbit Used as a loading control for 
Western Blot analysis 
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D. O2 Consumption Experiments in Model # 2 
After harvesting control hMSCs and GF treated hMSCs from Model # 2 (2.5 
weeks of GF treatment), O2 consumption experiments were performed by using 1.5 
million cells from each group. Control hMSCs and GF treated hMSCs were 
permeabilized by suspending with 4.5 µg/mL of digitonin in MiR05 and 1mM EGTA 
respiratory buffer for 5 minutes. Contents of MiR05 respiratory buffer are shown in Table 
4. After 5 minutes, cells were centrifuged at 1000 RPM for 5 minutes. The supernatant 
was removed and the cell pellets were re-suspended in 2 mLs of fresh MiR05 and 1mM 
EGTA respiratory buffer without digitonin. The 2 mLs from each group were injected 
into separate sealed chambers of the Oroboros O2K Oxygraph System. Equal amounts of 
O2 were also injected into both chambers containing the permeabilized hMSCs. The total 
O2 consumption and the O2 consumption rates were measured with the addition of the 
following mitochondrial specific substrates and inhibitors shown in Table 5. A visual 
model showing where the mitochondrial specific substrates and inhibitors act upon is 
visible in Figure 1.   
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Table 4: Contents of MiR05 Respiratory Buffer 
Name Final Concentration 
MgCl2·6H2O 3mM 
K-lactobionate 60mM 
Taurine 20mM 
KH2PO4 10mM 
HEPES 20mM 
Sucrose 110mM 
BSA 1 gram/L 
 
 
 
 
 
 
 
 
30 
 
Table 5: Summary of Mitochondrial Substrates and Inhibitors 
Name Substrate or Inhibitor Description 
5mM Pyruvate / 2mM Malate 
Complex I Substrates 
Substrates form NADH. 
NADH donates electrons to 
fuel Complex I (NADH 
Dehydrogenase) to initiate 
O2 consumption (state IV 
respiration) 
5mM ADP 
ATP Synthase Substrate / 
Energy Acceptor 
Substrate binds to ATP 
Synthase and triggers O2 
consumption (state III 
respiration) by stimulating 
oxidative phosphorylation 
5mM Succinate 
Complex II Substrate 
Substrate forms FADH. 
FADH donates electrons to 
fuel Complex II (Succinate 
Dehydrogenase) 
1ug/mL Rotenone 
Complex I Inhibitor 
An insecticide and fish 
poison that blocks electron 
transport between Complex I 
and ubiquinone 
1ug/mL Oligomycin 
ATP Synthase Inhibitor 
A macrolide antibiotic that 
blocks the proton channel of 
ATP Synthase 
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Figure 1: Electron Transport Chain (ETC) on the Inner Mitochondrial Membrane. 
Pyruvate, Malate, and Glutamate are Complex I substrates. Succinate is a Complex II 
substrate. Rotenone is a Complex I inhibitor. Oligomycin is an ATP Synthase inhibitor. 
Figure was provided by Dr. Anderson.  
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E. 2D and 3D Imaging with 3D Reconstruction in Model # 2 
Two dimensional (2D) laser scanning confocal imaging was performed on GF 
treated and control hMSCs to determine mitochondrial localization. Three dimensional 
(3D) laser scanning confocal imaging with 3D reconstruction was also performed to 
evaluate changes in 3D cell morphology in GF treated vs. control hMSCs to quantitate 
3D mitochondrial morphology.   
1. 2D Imaging 
DsRed hMSCs (both control and GF treated) were imaged on a confocal 
microscope (Zeiss LSM 510) in media containing 10% FBS without phenol for 2D 
imaging at different culture times. The hMSCs (both control and GF treated) were 
imaged after 4 days as an early culture time point and imaged after 11 days as a later 
culture time point to observe mitochondrial localization.   
2. 3D Imaging 
The dsRed hMSCs were grown with and without GFs for 2 weeks. Control 
and GF treated hMSCs were removed from flasks using TrypLE express recombinant 
trypsin and re-suspended in dye media. The cytosolic dye Calcein AM (494 nm 
excitation and 517 nm emission, 1 µM) and nuclear dye Syto61 (628 nm excitation 
and 645 nm emission, 1 µM) were added to control and GF treated hMSCs. Syto61 
was used for labeling the nucleus. Calcein AM was used to label the cytoplasm. The 
fluorescent protein dsRed (545 nm excitation and 572 emission) was used to target 
the mitochondria. After incubation in both dyes for 15 minutes, hMSCs were washed 
with PBS and re-suspended in media containing 10% FBS without phenol before 
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imaging on the Olympus FV1000 confocal microscope. HMSCs were suspended 
between 2 glass coverslips and placed in a coverslip chamber to stabilize cell media 
and reduce cell motion.  During 3D confocal imaging, 1 µm crossections were 
acquired and averaged 24 image slices during Z stack acquisition. Image alignment of 
crossection slices was completed using an algorithm developed in Dr. Hu’s laboratory 
to minimize distortions in 3D reconstructions caused by potential cell motion 
(Ekpenyong et al. 73671J-73671J). Figure 2 shows 3D image segmentations of both 
control and GF treated hMSCs.  
3. 3D Reconstruction 
Imaging software developed in Dr. Hu’s laboratory was used to align and 
create 3D reconstructions of the hMSCs (Ekpenyong et al. 73671J-73671J). Pixels 
from each confocal image slice were sorted on a histogram analysis according to 
fluorescent intensity into 4 groups: background, cytoplasm, mitochondria, and 
nucleus. After separation of pixels into their correct compartments, the confocal 
images were assembled by interpolation, forming a stl file format for 3D viewing. 
This computer generated 3D reconstruction minimized errors in the z axis 
interpolation (along with random and systematic error) by employing a z scan 
correction factor and image processing methods (Ekpenyong et al. 73671J-73671J). 
The computer generated 3D reconstructions were used to quantitate overall cell 
morphology and mitochondrial morphology.    
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Figure 2: Segmentation of 3D Confocal Imaging in GF Treated hMSCs. A: A control 
hMSC with 24 crossection slices is shown in segmented (top to bottom) form where each 
crossection is 1 µm apart. Nucleus is shown in blue and mitochondria are shown in red. B: 
The same is shown for a GF treated hMSC in B.  
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III. RESULTS 
A. Cardiac and Mitochondrial Gene Expression 
1. Model # 1: Cardiomyocyte and hMSC Co-culture 
Cardiac and mitochondrial gene expression was measured in hMSCs after 48 
hours in co-culture. Figure 3 shows the results of qRT-PCR for cardiac gene 
expression. Figure 4 shows the results of qRT-PCR for mitochondrial gene 
expression. Results for all qRT-PCR co-cultured hMSC data are indicated as fold 
difference of control hMSCs. Error bars on figures represent the standard error of the 
mean (SEM). 
A significant increase in MEF2C was measured in co-cultured hMSCs vs. 
control hMSCs (p < 0.01). Expression of the transcription factor CAMTA-1 showed a 
slight decrease in co-cultured hMSCs vs. control; however, the decrease was not 
statistically significant (p = 0.09). Other cardiac genes in Table 2 were not evaluated 
using qRT-PCR in this model.    
Significant increases of mitochondrial gene expression were present in co-
cultured hMSCs compared to control. A significant increase in TFB1M, a 
mitochondrial transcription factor, was measured in co-cultured hMSCs compared to 
control hMSCs (p ≤ 0.05). A significant increase in the mitochondrial ETC complex 
III subunit, UQCRC1, was measured in co-cultured hMSCs compared to the control 
(p < 0.05). No significant differences in other mitochondrial genes evaluated in co-
cultured hMSCs vs. control hMSCs were measured as shown in Figure 4.     
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Figure 3: Cardiac Gene Expression in Co-culture model.  MEF2C showed significantly 
increased expression in co-cultured hMSCs compared to control hMSCs (p < 0.01). 
CAMTA-1 showed decreased expression in co-cultured hMSCs compared to control hMSCs; 
however, this decrease was not statistically significant (p = 0.09). The bars show mean ± 
SEM (n =3). 
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Figure 4: Mitochondrial Gene Expression in Co-culture model. UQCRC1 showed a 
significant increase of expression in co-cultured hMSCs compared to the control hMSCs (p < 
0.05). TFB1M was significantly increased in co-cultured hMSCs compared to the control 
hMSCs (p ≤ 0.05). NRF1, MFN2, UCP3, and MT-CO1 showed no significant difference in 
gene expression in co-cultured hMSCs compared to control hMSCs. The bars show mean ± 
SEM (n = 3).     
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2. Model # 2: GF Treated hMSC Monoculture 
Mitochondrial gene expression was measured in hMSCs after 48 hours of GF 
treatment. Figure 5 shows these results for TFB1M, UQCRC1, and NRF-1. Results 
for all qRT-PCR in GF treated hMSC data are indicated as fold difference of control 
hMSCs. Error bars on figures represent SEM. No significant difference in gene 
expression for mitochondrial genes evaluated was measured in GF treated hMSCs (48 
hours) vs. control hMSCs as shown in Figure 5 (p > 0.05). 
Cardiac and mitochondrial gene expression was measured in hMSCs after 2.5 
weeks of GF treatment. Figure 6 shows the results of qRT-PCR for cardiac gene 
expression. Figure 7 shows the results of qRT-PCR for mitochondrial gene 
expression. Overall, qRT-PCR showed high variability for hMSCs in the 2.5 week 
GF treated model. 
No significant difference in gene expression for cardiac genes evaluated was 
measured in GF treated hMSCs (2.5 weeks) vs. control hMSCs as shown in Figure 6. 
All cardiac genes in Table 2 were evaluated via qRT-PCR in this model.    
For mitochondrial gene expression, a significant increase in TFB1M was 
measured in GF treated hMSCs (2.5 weeks) compared to control hMSCs (p < 0.05). 
There was no significant difference in expression of the mitochondrial ETC complex 
III subunit, UQCRC1, in GF treated hMSCs (2.5 weeks) compared to control hMSCs 
as shown in Figure 7. No significant differences in the mitochondrial genes MFN2, 
MT-CO1, NRF-1, and UCP3 were measured in GF treated hMSCs (2.5 weeks) and 
control hMSCs (data not shown).  
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Figure 5: Mitochondrial Gene Expression in 48 hour GF Treated Model. No significant 
difference in gene expression for TFB1M, UQCRC1, and NRF-1 were measured in GF 
treated hMSCs (48 hours) compared to control hMSCs (p > 0.05). Results are represented as 
n = 3. The bars show mean ± SEM. 
0 
1 
2 
3 
4 
Control GF Treated 
F
o
ld
 D
if
fe
re
n
c
e
 
TFB1M 
0 
1 
2 
3 
4 
Control  GF Treated 
F
o
ld
 D
if
fe
re
n
c
e
 
UQCRC1 
0 
1 
2 
3 
4 
Control GF Treated 
F
o
ld
 D
if
fe
re
n
c
e
 
NRF-1 
40 
 
 
 
Figure 6: Cardiac Gene Expression in 2.5 Week GF Treated Model. There was no 
significant difference of cardiac gene expression in the GF treated vs. control hMSCs. For 
MEF2C, CAMTA-1, BNP, and Myocardin, results are represented as n = 3. For Cx43, results 
are represented as n = 2. The bars show mean ± SEM.    
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Figure 7: Mitochondrial Gene Expression in 2.5 Week GF Treated Model. TFB1M was 
significantly increased in GF treated hMSCs compared to control hMSCs at 2.5 weeks (p < 
0.05). There was no significant change of UQCRC1 expression in GF treated hMSCs 
compared to control hMSCs. The bars show mean ± SEM (n = 3).  
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B. Western Blot Analysis 
Results of the western blot analysis for mitochondrial ETC complex II, III, IV, V, 
Cx 43, and N-Cadherin are represented below in Figure 8 and Figure 9. Figure 8 
illustrates the protein bands from 2.5 week GF treated hMSCs and control hMSCs. 
Protein loading control was confirmed for all bands in Figure 8 via β-actin or Ponceau S 
staining. Compiled data from 4 experiments is shown in Figure 9.   
Mitochondrial ETC complex II showed increased protein expression in GF treated 
hMSCs compared control hMSCs as shown in Figure 8, and averaged a twofold increase 
of protein expression with 4 replicate experiments as shown in Figure 9. N-Cadherin 
showed increased protein expression in GF treated hMSCs compared control hMSCs as 
shown in Figure 8, and averaged a fourfold increase of protein expression with 4 replicate 
experiments as shown in Figure 9. No difference in mitochondrial ETC complex III 
protein expression in Figure 8 and Figure 9 resembles the qRT-PCR results for UQCRC1, 
the mitochondrial ETC complex III subunit.       
No significant differences in expression of the cardiac gap junction, Cx 43, and 
the mitochondrial ETC complex V were measured as shown in Figure 8 and Figure 9. 
Mitochondrial ETC complex I protein expression was also evaluated; however, bands 
were not visible at the completion of western blots suggesting a faulty antibody for 
complex I or lack of complex I expression in both hMSC groups compared to other 
mitochondrial ETC complex proteins. 
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Figure 8: Cardiac and Mitochondrial Protein Expression from 2.5 week GF treated 
hMSCs. Complex II and IV showed increase of expression with 2.5 weeks of GF treatment. 
Complexes III and V showed no difference in control and GF treated hMSCs.  For cardiac 
protein expression, Cx 43 gap junction showed no observable difference in GF treated 
hMSCs compared to control. N-Cadherin, a cardiac tight junction, showed a clear increase of 
expression with 2.5 weeks of GF treatment. Results shown are representative data. Equal 
protein loading for all data shown above was confirmed via β-actin or Ponceau S staining.      
 
44 
 
 
 
Figure 9: Cardiac and Mitochondrial Protein Expression in GF Model. Top graph: 
Protein expression of N-Cadherin and mitochondrial ETC complexes II-IV. Data represents 
the average normalized density of 4 separate experiments (n = 4) expressed as a percent of 
the control. Bottom graph: Protein expression of Cx 43 and mitochondrial ETC complex V. 
Data represents the average normalized density of 3 separate experiments (n = 3) expressed 
as a percent of the control.  
 
0 
50 
100 
150 
200 
250 
300 
350 
400 
450 
Control GF 
Treated 
Control GF 
Treated 
Control GF 
Treated 
Control GF 
Treated 
N-Cadherin Complex II Complex III Complex IV 
A
v
e
ra
g
e
 N
o
rm
a
li
z
e
d
 D
e
n
s
it
y
  
(%
 o
f 
C
o
n
tr
o
l)
 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
110 
Control GF Treated Control GF Treated 
Cx 43 Complex V 
A
v
e
ra
g
e
 N
o
rm
a
li
z
e
d
 D
e
n
s
it
y
  
(%
 o
f 
C
o
n
tr
o
l)
 
45 
 
C. O2 Consumption Experimental Data 
In Figure 10, a representative O2 consumption experiment conducted in the 2.5 
week GF treated model is shown. The top panel shows the O2 concentration in the 
chambers of the Oroboros O2K Oxygraph System. Over time, the top panel shows a 
decrease in O2 concentration. By taking the negative value of the slope in the top panel, 
the value for the O2 consumption rate is known and visible in the bottom panel. In O2 
consumption experiments, addition of substrates tends to increase O2 consumption while 
inhibitors such as Rotenone and Oligomycin tend to decrease O2 consumption. For the 
representative experiment shown in Figure 10, the rate of O2 consumption is higher in GF 
treated hMSCs compared to control hMSCs throughout the entire experiment.  
In Figure 11, the results of all viable O2 consumption experiments used with the 
control and GF treated hMSCs (2.5 weeks) are represented graphically. In Figure 11, 
there was increased O2 consumption across all substrate combinations for the GF treated 
hMSCs (2.5 weeks) compared to control hMSCs. Substrate combinations involving 
complex II showed the most noticeable increases in the GF treated hMSCs compared to 
control hMSCs during O2 consumption experiments. The increases in O2 respiration were 
due to the addition of specific mitochondrial ETC substrates and inhibitors, thus any 
changes in O2 consumption were strictly mitochondrial. However, once again like qRT-
PCR, the results were variable in the O2 consumption experiments; thus, any increases 
seen in the GF treated hMSCs compared to control hMSCs were not significant (p > 
0.05).   
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Figure 10: Representative Results of O2 consumption experiment. Top panel: O2 
concentration in the sealed incubation chamber of the Oroboros O2K Oxygraph System. 
Bottom panel: rate of O2 consumption in the hMSCs. Notice the rate of O2 consumption is 
higher in GF treated hMSCs throughout the entire experiment.  
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Figure 11: GF treatment on O2 consumption in hMSCs. O2 consumption rates were 
assessed in the presence of excess concentration of Pyruvate and Malate alone (P/M), 
Pyr/Mal with maximum concentration of ADP (P/M + ADP), Pyr/Mal and ADP with 
Succinate, (P/M + Succ + ADP), and Succinate with ADP (Succ + ADP + Rotenone). 
Rotenone acts as a Complex I inhibitor. Note the increase in rates of O2 consumption with 
2.5 weeks of GF treatment across all substrate combinations even though there was no 
significant difference in O2 consumption between control and GF treated hMSCs. The bars 
show mean ± SEM. (n=3). 
 
 
 
 
 
 
0 
5 
10 
15 
20 
25 
30 
35 
40 
45 
50 
55 
Complex I 
basal 
Complex I max 
ADP 
Complex I+II 
max ADP 
Complex II 
max ADP 
P/M P/M +ADP P/M + Succ + 
ADP 
Succ + ADP + 
Rotenone 
O
2 
co
n
su
m
p
ti
o
n
  
p
m
o
l ·
 s
-1
 ·
 m
ill
io
n
 c
e
lls
-1
 
Control 
Treated 
48 
 
D. 2D and 3D Imaging with Reconstruction Analysis 
The results from 2D imaging showed a change in mitochondrial localization for 
control and GF treated hMSCs with increased time in culture. The results from 3D 
imaging and reconstruction followed by analysis revealed a unique mitochondrial 
morphology in GF treated hMSCs compared to control hMSCs.  
1. 2D Imaging – Mitochondrial Localization 
The results from 2D imaging are shown in Figure 12. At early culture times (4 
days in culture), both the control and GF treated hMSCs showed perinuclear 
mitochondrial localization. In both the control and GF treated hMSC groups at later 
culture times (11 days in culture), mitochondria distributed throughout cytoplasm and 
appeared to show increased mitochondrial content. No method was available to 
measure any differences between control hMSCs and GF treated hMSCs, thus leaving 
this analysis as a potential future study.  
2. 3D Imaging and Reconstruction 
The computer generated 3D reconstructions for control and GF treated 
hMSCS are shown in Figure 13. A crossection image is shown in Figure 13 as a 3D 
confocal image slice and as part of a computer generated reconstruction for control 
and GF treated hMSCs. In addition, a 3D computer generated surface rendering is 
also being shown in Figure 13.      
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Figure 12: 2D Imaging Results showing Mitochondrial Localization in GF Treated 
Model. In early cultures, mitochondria were less abundant and perinuclearly localized. At 11 
days in culture, mitochondrial content increased and distributed throughout the cytoplasm.   
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Figure 13: 3D hMSC Imaging and Reconstruction. Control: Top left image shows a 1 µm 
crossection of a control hMSC. The outline of the cell is shown by the white dashes. The 
mitochondria are shown in red, and the nucleus is shown in blue. The bottom left image 
shows a computer generated 3D reconstruction of the cell at the same crossectional area with 
the mitochondria shown in green. The reconstruction on the right is a 3D surface rendering of 
the cell. GF Treated: Similar images of GF treated hMSCs are shown in the right panel.    
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3. 3D Reconstruction Morphological Analysis 
The 3D reconstructions were used to quantify mitochondrial morphology. 
Over 80 cells were imaged for each group in Model # 2 (control and GF treated 
hMSCs); however, Table 6 shows the preliminary analysis results of overall cell 
morphology for 25 hMSCs each.  The cell surface area and volume were used as 
controls in this experiment to ensure no difference in cell size between control and 
GF treated hMSCs. Nuclear surface area and volume showed a statistical significant 
increase in GF treated hMSCs compared to control hMSCs. The nucleus to cell 
volume ratio showed a statistical significant increase in GF treated hMSCs compared 
to GF treated hMSCs. The index of surface irregularity in Table 6 refers to 
irregularities such as bumps, roughness, or folds on a smooth surface. A large value 
for the index of surface irregularity indicates many irregularities on a surface. No 
significant difference was measured for the index of surface irregularity in the 
nucleus for control and GF treated hMSCs.  
Mitochondrial surface area and volume showed a statistical significant 
increase in GF treated hMSCs compared to control hMSCs. The surface to volume 
ratio of mitochondria showed an increase that was close to significance in GF treated 
hMSCs compared to control hMSCs (p = 0.054). No significant difference was 
measured for the mitochondrion to cell volume ratio between GF treated hMSCs and 
control hMSCs. 
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Table 6: 3D Morphological parameters  
 
PARAMETER 
 
UNIT 
MEAN STARDARD DEVIATION 
p 
Control (n=25) GF treated (n=25) 
Cell surface area m
2
 30.561 8.93 28.261 9.59 0.438 
Cell volume m
3
 454.15 161 384.25 163 0.438 
Nucleus 
Nuclear surface area m
2
 18.900 4.98 24.257 9.100 0.026 
Nuclear volume m
3
 194.50 91.481 281.30 126.778 0.018 
Volume ratio of nucleus to cell - 0.4274 0.2122 0.7225 0.158 <0.001 
Index of surface irregularity of 
nucleus 
m
-1/2
 201.41 36.3 204.52 54.4 0.883 
Mitochondria 
Mitochondrial surface area m
2
 90.593 151 277.15 317 0.023 
Mitochondrial volume m
3
 71.20 109.314 205.30 228.853 0.023 
Index of surface irregularity of 
mitochondria 
m
-1/2
 1038.7 1135 2068.5 1783 0.036 
Surface to volume ratio of 
mitochondria 
m
-1
 0.9456 0.261 1.1167 0.282 0.054 
Volume ratio of mitochondrion 
to cell - 0.2048  1.0359  0.080 
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IV. DISCUSSION 
A. Conclusions 
Overall, the main objective of this study was to improve the basic understanding 
of adult stem cell differentiation in cardiac tissue regeneration and repair by investigating 
the role of mitochondrial biogenesis in adult hMSC differentiation and acquisition of a 
cardiac phenotype in a simulated cardiac co-culture microenvironment (Model # 1) and in 
a GF treated monoculture model (Model # 2). To that end, the main results of this 
investigation for Model # 1 and Model # 2 are summarized below: 
- Model # 1 (Co-cultured hMSCs) 
 Increased cardiac and mitochondrial gene expression 
- Model # 2 (GF treated hMSCs) 
 Increased mitochondrial gene expression 
 Increased cardiac and mitochondrial protein expression 
 Increased mitochondrial O2 consumption 
 Increased mitochondrial surface area, volume, and surface irregularity 
In Model # 1 and Model # 2, mitochondrial biogenesis is evident. For Model # 1, 
mitochondrial gene expression of TFB1M and UQCRC1 was significantly increased in 
co-cultured hMSCs vs. control hMSCs. In Model # 2, no difference in mitochondrial 
gene expression was observed at 48 hours suggesting that mitochondrial biogenesis 
signaling may occur at different time points in Model # 1 and Model # 2. For Model # 2 
at 2.5 weeks, mitochondrial gene expression showed a significant increase in TFB1M. 
Western blot analysis suggests a trend in protein expression for complexes II and IV. 
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Increased mitochondrial O2 consumption for all mitochondrial substrate combinations 
was observed in 2.5 week GF treated hMSCs compared to control hMSCs where 
substrate combinations utilizing complex II were closest to significance. 3D imaging, 
reconstruction, and analysis revealed a unique mitochondrial morphology in GF treated 
hMSCs. Mitochondrial surface area and volume along with increased mitochondrial 
surface irregularities showed significant increases in GF treated hMSCs compared to 
control hMSCs. In summary, Model # 1 showed early signaling and changes of 
mitochondrial biogenesis at 48 hours. While mitochondrial biogenesis was not observed 
at this early time point in Model # 2, it was evident at 2.5 weeks in GF treated hMSCs.    
Model # 1 and Model # 2 show changes in mitochondrial biogenesis. However, 
was this biogenesis involved in hMSC acquisition and differentiation into a cardiac 
phenotype? In Model # 1, cardiac gene expression of MEF2C was significantly increased 
in co-cultured hMSCs vs. control hMSCs. But, in Model # 2, cardiac gene expression did 
not change over 2.5 weeks. Furthermore, cardiac protein expression of N-cadherin only 
suggested a trend for increased expression in GF treated hMSCs. In addition, in Model # 
1, mitochondrial ETC complex III expression may play a role in early hMSC 
differentiation into a cardiac phenotype. In Model # 1, UQCRC1 (complex III subunit) 
gene expression was significantly increased in co-cultured hMSCs vs. control hMSCs. In 
Model # 2, no difference in UQCRC1 gene expression was found at 48 hours and 2.5 
weeks. Furthermore, no difference in complex III protein expression was observed for 
Model # 2 at 2.5 weeks suggesting no differences overall for complex III expression in 
Model # 2 and a potential reason for the lack of cardiac-like differentiation in GF treated 
hMSCs. Complex III upregulation may be necessary for hMSC differentiation in Model # 
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1 because complex III expression has been shown to be necessary for embryonic stem 
cell and hMSC differentiation into lineages such as fat, bone, and muscle ((Spitkovsky et 
al. ; Tormos et al. 537-544; Varum et al. 142-156). Future studies are needed to explore 
the importance of complex III in hMSC differentiation in Model # 1. Based on the results 
of this investigation, Model # 1 may be a better model for directing hMSCs to a cardiac 
like fate compared to Model # 2. Thus, Model # 1 supported the hypothesis that 
mitochondrial activity and biogenesis would be enhanced when hMSCs were directed 
towards a cardiac-like fate while Model # 2 did not fully support this hypothesis. 
Model # 2 suggests enhanced mitochondrial biogenesis with increased time in 
culture when treated with GFs may lead to improved hMSC survival and proliferation. 
One study has shown that pre-treatment with GFs improves therapies when hMSCs are 
transplanted into the cardiac environment by enhancing engraftment and by limiting 
infarct size and apoptosis; this study has proposed increased gap junction function to be a 
factor of these therapeutic enhancements without providing strong support for its causal 
connection in improved therapies (Hahn et al. 933-943). However, mitochondrial 
biogenesis in GF treated hMSCs may also be a factor in improved hMSC therapies based 
on Model # 2’s results. The role of mitochondrial biogenesis in adult stem cell survival 
and therapies for cardiac tissue regeneration and repair has not been explored. Thus 
further studies must determine if a relationship exists between enhanced gap junction 
function and enhanced mitochondrial biogenesis in stem cell survival when transplanted 
into a cardiac environment.    
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B. Study Limitations 
There were study limitations present in this investigation. Many of these 
limitations were from Model # 1 (the 48 hour Co-culture model). The short culture time 
of Model # 1 may be considered one of its limitations. The culture time of the co-culture 
model was short (only 48 hours) compared to Model # 2 (the 2.5 weeks GF model) due to 
several reasons.  The first reason for this short culture time in Model # 1 was attributable 
to the strong connections between the hMSCs and the cardiomyocytes developed over 
time in this model. The cells become intertwined and difficult to separate for other 
experiments when allowed to grow in co-culture for long periods of time. On the other 
hand, at earlier time points in the co-culture model, the hMSCs were more mobile thus 
easing the separation process from cardiomyocytes.  
The second reason for keeping a short culture time in this model was due to a 
dilution effect created by the hMSCs. From previous investigations, it was hypothesized 
that direct cell-cell contact with cardiomyocytes (and not juxtacrine and paracrine 
factors) in the co-culture model is necessary for hMSC acquisition and differentiation of 
a cardiac-like phenotype (Muller-Borer et al. e38454). With time in culture, hMSCs grow 
and proliferate. Due to hMSC proliferation, a fixed amount of hMSC-cardiomyocyte cell 
contacts in co-culture are outnumbered by proliferating hMSCs not in contact with the 
cardiomyocytes. As hMSCs continued to increase, the hMSCs (showing potential to 
differentiate into cardiomyocytes) in contact with the cardiomyocytes were diluted by the 
influx of other hMSCs. This dilution affected other experiments such as gene expression 
causing misrepresentation of hMSCs desired for study. Furthermore, if this culture was 
prolonged, hMSCs began to take most of the nutrients and space present for both cell 
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types in co-culture. The cardiomyocytes began to die from lack of nutrients by the 
aggressive growth and proliferation of hMSCs.  
The short culture time created another limitation in the co-culture model. A low 
hMSC yield due to the short culture time was the second limitation of this model. By 
having a short culture time, proliferation of hMSCs was limited and fewer hMSCs were 
available for analysis. The low yield of hMSCs was also caused by several other reasons. 
The 1:10 ratio of hMSCs to cardiomyocytes was one of the reasons why the co-culture 
model yielded a low number of hMSCs. The addition of a small number of hMSCs to a 
large number of cardiomyocytes for a short culture time did not produce enough hMSCs 
for many experiments. Another reason for low cell yield in this model was due to the 
separation of hMSCs from cardiomyocytes. The hMSC separation from cardiomyocytes 
greatly reduced the amount of hMSCs grown in co-culture. Different separation methods 
were evaluated to gain the highest hMSC yield.        
Two different attempts were made at separating the hMSCs from the 
cardiomyocytes. The first attempt included FACS sorting hMSCs. Two cell groups were 
used to evaluate FACS sorting as a viable separation method of the hMSCs from the 
cardiomyocytes. Both cell groups were hMSC monocultures grown at incubator 
conditions with full media for 2.5 weeks like the control hMSCs from Model # 2. The 
first group of cells labeled as FACS Sorted hMSC Monoculture was FACS sorted. The 
second group of cells labeled as Non-sorted hMSC Monoculture was not FACS sorted. 
After FACS sorting, the FACS Sorted hMSC Monoculture returned a low cell yield 
limiting other follow-up experiments. Because of a low cell yield, the viability of the 
sorted hMSCs and the experimental technique of the FACS separation were questioned. 
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Thus, evaluation of FACS sorting hMSCs on hMSC’s metabolic activity and viability 
was completed by a mitochondrial O2 consumption experiment between the Non-sorted 
hMSC Monoculture and the FACS Sorted hMSC Monoculture. The Results of the O2 
consumption experiment are shown in Figure 14.    
From the Results shown in Figure 14, FACS Sorted hMSCs were more 
metabolically active compared to hMSCs that were not FACS sorted. Higher rates of O2 
consumption were seen in the FACS sorted hMSCs during the addition of the substrate 
ADP and the complex II substrate Succinate. From the Results in Figure 14, it was 
evident that the FACS sorting selected for more robust and metabolically active hMSCs 
than the overall population of non-sorted hMSCs. One explanation suggested for this odd 
occurrence is due to the heterogeneity of the hMSC population before FACS sorting. The 
non-sorted hMSCs may have the ability to differentiate into many divergent cell types 
with different metabolic profiles. FACS sorting possibly selected for a certain group of 
hMSCs thus creating a small homogeneous population of hMSCs with a higher metabolic 
profile compared to the large heterogeneous population of non-sorted hMSCs. 
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Figure 14: O2 Consumption of FACS Sorted vs. Non-sorted hMSC Monocultures. Note 
the higher respiration of FACS sorted hMSCs with the addition of ADP and the complex II 
substrate Succinate.     
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FACS was also used to sort hMSCs in Model # 1. When control (monoculture) 
and co-cultured hMSCs were separated by FACS, both groups of hMSCs also showed 
low cell yield similar to the sorted hMSC monoculture (2.5 week culture). The co-
cultured hMSCs with cardiomyocytes approached only a 30% cell yield after separation 
by FACS. Due to a low cell yield in both the monoculture hMSCs and the co-cultured 
hMSCs, and higher metabolic profiles established in the hMSC monocultures from FACS 
sorting; FACS separation technique was not an ideal method due to limited number and 
skewed representation of hMSCs that arose from it.       
The second attempt at separating the hMSCs from the cardiomyocytes in co-
culture was the CD 90 magnetic bead separation. The cell yield using the magnetic bead 
separation approached 50% in Model # 1. Therefore, hMSC separation from 
cardiomyocytes with CD 90 magnetic beads returned a higher yield of cells compared to 
FACS separation. Because of the higher yield of hMSCs compared to FACS separation, 
magnetic bead separation was used to separate hMSCs from cardiomyocytes for this 
investigation. However, magnetic bead separation also produced an inadequate hMSC 
yield from co-culture separation for other experiments. 
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C. Future Studies 
1. Model # 1 – 48 Hour Co-culture Model 
Due to study limitations in the co-culture model, expansion of experimental 
measurements or substitution of this model must be done. For future studies, 
experimental measurements can be expanded in Model # 1 even with study 
limitations of low cell yields. In order to expand experimental measurements with 
low hMSC yield, microscopy is one possibility for this model. Microscopy uses fewer 
cells than other experiments such as qRT-PCR, western blots, and mitochondrial O2 
consumption; thus, making it an optimal choice of study for Model # 1. Two 
microscopy investigations are suitable for expanding experimental measurements in 
this model.  
The first microscopy investigation should include 3D imaging and 
reconstruction. By taking 3D images on a confocal microscope, valuable data 
concerning mitochondrial morphology may be quantified as done in Model # 2 using 
the computer generated reconstructions. In addition, 2D imaging may also be 
completed in Model # 1 to provide knowledge on mitochondrial localization. 
Differences at early culture times in control and co-cultured hMSC mitochondrial 
distribution will be elucidated. Furthermore, 2D imaging can also be completed at 
later culture times because co-cultured hMSCs do not need to be separated from 
cardiac myocytes as done for qRT-PCR. The hMSCs are transduced with a lentiviral 
vector encoding for the fluorescent protein, dsRed, which targets mitochondria and 
identifies hMSCs from cardiac myocytes in confocal microscopy. By completing the 
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first microscopy investigation, further data will be established on the similarities of 
mitochondrial distribution and morphology in Model # 1 and Model # 2.  
The first microscopy investigation can be completed to provide data on 
mitochondrial distribution and morphology, while the second microscopy 
investigation should be completed to provide data on mitochondrial master regulator 
proteins necessary for mitochondrial biogenesis. By studying the behavior of these 
master regulators in microscopy, further evidence could be used to potentially support 
the results of qRT-PCR in Model # 1. One potential example for the second 
microscopy investigation is to study the location of NRF-1 in co-cultured hMSCs vs. 
control hMSCs. The results of qRT-PCR revealed no significant differences in NRF-
1; however, lack of difference in expression does not explain the location of NRF-1 in 
hMSCs. In the presence of intracellular Ca
2+
 or potentially with Ca
2+
 oscillations, 
NRF-1 moves from the cytoplasm into the nucleus to turn on genes further down in 
the mitochondrial biogenesis signaling pathway (Chau, Evans, and Scarpulla 6999-
7006; Gugneja, Virbasius, and Scarpulla 5708-5716; Gugneja and Scarpulla 18732-
18739; Murakami et al. 113-122; Virbasius, Virbasius, and Scarpulla 2431-2445). By 
having a higher nuclear to cytosolic ratio of NRF-1 in co-cultured hMSCs vs. control 
hMSCs (with a co-culture model known for Ca
2+
 oscillations) suggests NRF-1 is 
involved with mitochondrial biogenesis even though no difference in gene expression 
was revealed with qRT-PCR (Muller-Borer et al. e38454). If what is proposed for 
NRF-1 has been found to be supported in Model # 1, then it immediately suggests a 
mitochondrial biogenesis signaling pathway that may be involved in the cardiac 
differentiation of hMSCs.  
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Substitutions in the co-culture model must be done in order to further study 
and elucidate the mitochondrial biogenesis pathway in hMSC acquisition and 
differentiation of a cardiac phenotype.  One substitution in Model # 1 that can be 
completed may be siRNA experiments. CAMTA-1, a cardiac gene evaluated in 
Model # 1, has been shown to be necessary in hMSC differentiation into a cardiac 
like phenotype in Model # 1 by loss of function siRNA experiments (Muller-Borer et 
al. e38454). When CAMTA-1 gene expression was knocked down by CAMTA-1 
siRNA, cardiac gene expression was also minimized. The CAMTA-1 siRNA provides 
an opportunity for future studies in determining if the mitochondrial biogenesis 
signaling pathway is directly integrated in hMSC cardiac-like differentiation of 
Model # 1. After CAMTA-1 siRNA is used for hMSCs in co-culture and the second 
microscopy investigation is completed in Model # 1, qRT-PCR can be used to 
evaluate NRF-1 gene expression, and microscopy can be used to evaluate NRF-1’s 
nuclear to cytosolic ratio in order to determine if CAMTA-1 is necessary for NRF-1 
gene expression and recruitment to the nucleus for activation of the mitochondrial 
biogenesis signaling pathway. In addition, other mitochondrial gene expression 
(specifically UQCRC1) may be evaluated in order to determine if CAMTA-1 gene 
expression is necessary to turn on other mitochondrial genes such as UQCRC1. After 
determining UQCRC1’s involvement in hMSC acquisition and differentiation into a 
cardiac-like phenotype, the necessity of UQCRC1 in this process can be verified by 
using UQCRC1 siRNA (or other complex III genes) in Model # 1 and evaluating 
differences in cardiac gene expression.  
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If the future studies proposed are completed, the importance of mitochondrial 
biogenesis in this model will be clarified. Thus, from the results obtained in this 
investigation and the results found in the literature, the signaling pathway in Figure 
15 is hypothesized. This hypothesis suggests intracellular Ca
2+
 and Ca
2+
 oscillations 
turn on CAMTA-1, and CAMTA-1 activates cardiac gene expression in Model # 1. 
Future studies will either support the hypothetical signaling pathway or reject it by 
determining if CAMTA-1 is necessary for mitochondrial gene expression (and NRF-1 
localization) and if mitochondrial gene expression is necessary for cardiac gene 
expression and differentiation.     
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Figure 15: Hypothetical Mitochondrial Biogenesis Signaling Pathway in Model # 1. Ca
2+
 
has been known to activate CAMTA-1 and eventually MEF2C and other cardiac genes. 
However, mitochondrial biogenesis in this differentiation pathway is not known for this 
model. Results from this investigation and future studies propose CAMTA-1 maintains NRF-
1 gene expression and localization. NRF-1 localization in the nucleus suggests activation of 
mitochondrial biogenesis pathway by turning on the genes TFB1M and UQCRC1. 
Furthermore, UQCRC1 and other complex III genes are necessary for activating MEF2C and 
other cardiac genes.  
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2. Model # 2 – GF Treated Model 
Future studies can also be completed in Model # 2. The literature has shown 
that hMSCs treated with GFs express enhanced gap junction function, and this 
enhanced gap junction function increases therapeutic efficiency by reducing infarct 
size and improving cardiac function in a rat myocardial infarction model (Hahn et al. 
933-943). However, this enhanced gap junction function was only observed after the 
GF treated hMSCs were co-cultured with rat cardiac myocytes or when placed in the 
myocardial infarction model (Hahn et al. 933-943). No enhanced gap junction 
function and no difference in Cx 43 protein expression were observed when GF 
treated hMSCs were not co-cultured with cardiac myocytes (Hahn et al. 933-943). No 
difference in Cx 43 protein expression in the literature correlates with results of Cx 43 
gene and protein expression in this investigation for Model # 2.  
Future studies can determine if gap junction function is enhanced solely with 
GF treatment (and not supplemented by co-culture with cardiac myocytes) to ease 
pre-treatment for future therapies. Even with no differences in Cx 43 gene and protein 
expression, other measurements can be completed to determine if gap junction 
function is enhanced solely with GF treatment. These measurements include 
Fluorescence Recovery After Photobleaching (FRAP) and immuoncytochemistry.     
Fluorescence Recovery After Photobleaching (FRAP) should be completed to 
determine overall physiological gap junction function. If there is increased 
fluorescence recovery in one group of cells compared to a second group of cells after 
photobleaching with a confocal microscope, then the first group would show 
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intensity at any given time after photobleaching (Wade, Trosko, and Schindler 525-
528; Abbaci et al. 50-61). 
When the rate constant for a specific transfer of fluorescent molecules is large, 
the rate of transfer is fast. Results of the rate constants K1 and K2 are shown in 
Figure 17. Notice the values for the rate constants K1 and K2 are significantly 
increased with GF treatment as shown in Figure 17. These results suggest the 
exchange rate of fluorescent molecules is larger with GF treatment. Increased 
fluorescent recovery in GF treated hMSCs is due to facilitated diffusion caused by 
open gap junctions and could be due to increased gap junctions compared to the 
control hMSCs.       
Several experimental controls should be observed to validate any results from 
FRAP experiments. The experimental control observed above in Figure 18 is the 
depth of photobleaching. The depth of photobleaching is the change of normalized 
fluorescent intensity from the original percent value to the first measured normalized 
intensity percent value immediately at the end of photobleaching. If the depth of 
photobleaching is significantly different between groups, then the rate of recovery 
and the intensity of fluorescence recovered may be affected resulting in skewed data. 
Figure 18 shows no significant difference in the depth of photobleaching between the 
control and GF treated groups of hMSCs. The second experimental control observed 
is the bleach time. If the bleach times are significantly different, then the increased 
rate of recovery and an increased fluorescent intensity recovered can be due to a 
shorter bleach time. Figure 19 shows no significant difference in the bleach time 
between the control and GF treated groups.    
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Figure 16: Preliminary FRAP Results on 2.5 Week GF Treated Model (Model # 2). 
Cells were labeled with the cytosolic dye Calcein AM. The FRAP procedure was completed 
with a staging incubator system on a laser scanning confocal microscope (LSM 710) where 
the conditions were at 37°C and 5% CO2. Note the increase and the speed in FRAP with GF 
treatment. Results are represented as n = 1 (5 observations per group).  
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Figure 17: Rate Constant Mean Values of FRAP. The mean of the rate constants K1 and 
K2 are graphed above with the units [1/s]. The high value rate constant indicates a fast 
fluorescence recovery. Note the GF treated group shows larger values for the rate constants. 
The bars show mean ± SEM. A significant difference between the control group and the GF 
treated group for both rate constants K1 and K2 was observed (p < 0.05). Results are 
represented as n = 1 (5 observations per group).  
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Figure 18: Depth of Photobleaching in FRAP. The depth of photobleaching is the initial 
loss of fluorescence caused by photobleaching. A Significant difference in depth of 
photobleaching may skew FRAP results. Thus having a similar depth of photobleaching 
serves as an experimental control. There was no significant difference in the control group 
versus the GF treated group (p > 0.05). The bars show mean ± SEM. Results are represented 
as n = 1 (5 observations per group).  
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Figure 19: Average Bleach Time in FRAP. The average bleach time is the time for 
photobleaching to occur. Similar to the depth of photobleaching, significantly different 
average bleach times may skew FRAP results. Thus having a similar average bleach time 
serves as an experimental control. There was no significant difference in control hMSCs 
versus GF treated hMSCs (p > 0.05). The bars show mean ± SEM. Results are represented as 
n = 1 (5 observations per group).   
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The speed and increase in FRAP along with increased rate constants with GF 
treatment suggest enhanced gap junction function in GF treated hMSCs vs. control 
hMSCs. FRAP will have to be repeated in order to establish reproducibility on 
enhanced gap junction function. If enhanced gap junction function is evident after 
repeating the FRAP experiment, then specific gap junctions being enhanced from 
solely GF treatment must be determined. The literature has suggested Cx 43 to be one 
of these enhanced gap junctions when GF treated hMSCs were co-cultured with 
cardiac myocytes (Hahn et al. 933-943). Thus, Cx 43 may be one of the enhanced gap 
junctions present in GF treated hMSCs before co-culturing with cardiac myocytes. 
However, with no difference in Cx 43 gene and protein expression with GF treatment 
alone, Cx 43 is unlikely to be one of the enhanced gap junctions represented from the 
results of FRAP. Immunocytochemistry can be completed to confirm Cx 43 gene and 
protein expression.  
Figure 20 shows images of control hMSCs and GF treated hMSCs stained 
with Cx 43. Cx 43 is represented as gap junctions with a green punctuate pattern 
lining the edges and connections of the hMSCs. The control hMSCs and GF treated 
hMSCs appear to be similar; however, no differences must be confirmed with 
fluorescent intensity after further image analysis. If there is no difference in control 
and GF treated hMSCs when FRAP has suggested enhanced gap junction function, 
then other cardiac gap junctions (Connexin 40 and 42) or non-cardiac gap junctions 
will have to be evaluated to determine the specific gap junction enhanced. If non-
cardiac gap junction functions are enhanced, then data from Model # 2 suggests GF 
treated hMSCs are not differentiating towards a cardiac-like phenotype.       
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In addition to gap junction functional studies, the effects of mitochondrial 
biogenesis in hMSC survival and proliferation studies must be evaluated in GF 
treated hMSCs. One future study would be to administer mitochondrial ETC complex 
toxins for complex II (carboxin), complex III (antimycin A), and complex IV 
(cyanide and azide); and determine if GFs evaluated in this investigation recovers 
mitochondrial biogenesis, hMSC survival (propidium iodide, cell cycle analysis, and 
mitochondrial membrane potential flow cytometry assessment), and proliferation 
(wound healing assays). Overall, in Model # 1 and Model # 2, many future studies are 
pursuable based on the results implicated in this investigation.    
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Figure 20: Immunocytochemistry of Cx 43 in Control and GF Treated hMSCs. The 
images were taken at 2.5 weeks. Notice the punctate green lines and connections showing the 
Cx 43 gap junctions along the hMSCs. The Cx 43 gap junctions in these images are shown at 
the edges of the hMSCs where they make connections with other hMSCs. The left image 
shows a control hMSC, and the right image shows a GF treated hMSC. The location of the 
Cx 43 gap junctions in GF treated hMSCs appears to be similar to control hMSCs. 
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